Pparδ agonist 5

• Description :

  Pparδ agonist 5, an orally active PPARδ-selective agonist (EC50=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo[1].

• UNSPSC :

  12352005

• Target :

  PPAR

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/pparδ-agonist-5.html

• Solubility :

  10 mM in DMSO

• Smiles :

  OC(/C=C/C1=CC=C(N(C)CC2=C(C)N=C(C3=CC=C(C(F)(F)F)C=C3)S2)C=C1C)=O

• Molecular Formula :

  C23H21F3N2O2S

• Molecular Weight :

  446.49

• References & Citations :

  [1]Kress BJ, et al. Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis. J Med Chem. 2021;64 (10) :6996-7032.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PPARδ